Floatz logo

URABRELIMAB

Advanced Solid Cancers

Surface Oncologymonoclonal_antibodyPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Advanced Solid Cancers cohort.

Asset / SponsorPhaseRating
FENTANYL
Gachon University Gil Medical Center
Phase 2B
prl3-zumab
Intra-IMMUSG Pte Ltd
Phase 2/3B
Oxycodone
Gachon University Gil Medical Center
Phase 2B
Zalifrelimab
Agenus Inc.
Phase 1/2CCC
Memory-Like Nk Cells
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2CC

View all 22 →

Same molecule, other indications

URABRELIMAB is also rated in:

hematopoietic and lymphoid system neoplasmDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →